Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

GOSS

Gossamer Bio Inc

Dec 13 • 04:00PM ET

0.9300

Dollar change +0.0200
Percentage change 2.20	%

Healthcare • Biotechnology • USA • NASD

Peers: BLUE CRSP SRPT FATE NTLA ADAP EDIT QURE BMRN VYGR

| Held by: VTI VXF SCHA VHT SCHB RFLR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.33	Insider Own	23.20%	Shs Outstand	226.60M	Perf Week	23.47%
Market Cap	215.37M	Forward P/E	-	EPS next Y	-0.71	Insider Trans	0.95%	Shs Float	174.03M	Perf Month	14.03%
Income	-71.65M	PEG	-	EPS next Q	-0.17	Inst Own	57.01%	Short Float	3.66%	Perf Quarter	2.20%
Sales	105.32M	P/S	2.04	EPS this Y	76.06%	Inst Trans	-4.63%	Short Ratio	5.05	Perf Half Y	78.85%
Book/sh	0.24	P/B	3.89	EPS next Y	-151.33%	ROA	-20.51%	Short Interest	6.38M	Perf Year	-13.08%
Cash/sh	1.41	P/C	0.66	EPS next 5Y	5.20%	ROE	-90.26%	52W Range	0.50 - 1.60	Perf YTD	1.92%
Dividend Est.	-	P/FCF	-	EPS past 5Y	11.99%	ROI	-27.99%	52W High	-41.88%	Beta	1.88
Dividend TTM	-	Quick Ratio	6.74	Sales past 5Y	0.00%	Gross Margin	96.14%	52W Low	86.26%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	6.74	EPS Y/Y TTM	81.97%	Oper. Margin	-59.64%	RSI (14)	67.93	Volatility	14.47% 8.33%
Employees	135	Debt/Eq	3.76	Sales Y/Y TTM	-	Profit Margin	-68.03%	Recom	1.25	Target Price	8.67
Option/Short	Yes / Yes	LT Debt/Eq	3.73	EPS Q/Q	34.38%	Payout	-	Rel Volume	1.93	Prev Close	0.91
Sales Surprise	11.14%	EPS Surprise	4.89%	Sales Q/Q	-	Earnings	Nov 07 AMC	Avg Volume	1.26M	Price	0.93
SMA20	26.63%	SMA50	9.88%	SMA200	2.54%	Trades		Volume	2,436,638	Change	2.20%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-25-24	Initiated	Oppenheimer	Outperform	$9
Apr-05-24	Resumed	Wedbush	Outperform	$4
Jul-27-23	Downgrade	UBS	Buy → Neutral	$8 → $1.25
Mar-07-23	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-23	Initiated	Guggenheim	Neutral
Dec-07-22	Downgrade	SMBC Nikko	Outperform → Neutral	$3
Dec-07-22	Downgrade	JP Morgan	Neutral → Underweight
Dec-07-22	Downgrade	Barclays	Overweight → Equal Weight	$18 → $2
Oct-20-22	Initiated	Goldman	Buy	$22
Sep-21-22	Initiated	JP Morgan	Neutral	$17
Sep-19-22	Initiated	Wedbush	Outperform	$24
Apr-18-22	Initiated	Raymond James	Outperform	$19
Apr-06-22	Initiated	UBS	Buy	$19
Jan-10-22	Upgrade	SMBC Nikko	Neutral → Outperform	$24
Nov-09-21	Resumed	Cantor Fitzgerald	Overweight	$20
Sep-21-21	Resumed	Piper Sandler	Overweight	$26
Jun-29-20	Initiated	H.C. Wainwright	Buy	$31
Apr-22-20	Initiated	Piper Sandler	Overweight	$30
Feb-27-20	Initiated	Barclays	Overweight	$21
Dec-03-19	Resumed	BofA/Merrill	Buy

Show Previous Ratings

Nov-21-24 12:00PM	All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy (Zacks)
Nov-15-24 09:35AM	After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) (Zacks)
Nov-14-24 09:35AM	After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) (Zacks) -5.59%
Nov-11-24 04:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-24 06:00PM	Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:59PM	Loading…
04:59PM	Gossamer Bio: Q3 Earnings Snapshot (Associated Press Finance)
04:03PM	Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Oct-31-24 07:00AM	NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule (GlobeNewswire)
Oct-30-24 07:00AM	Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now (GlobeNewswire)
Oct-29-24 07:00AM	Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now (GlobeNewswire)
Oct-07-24 05:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-25-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 2 on September 26 (GlobeNewswire)
Sep-24-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now (GlobeNewswire)
Aug-26-24 04:01PM	Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024 (Business Wire)
Aug-21-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
07:00AM	Loading…
Aug-20-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire)
Aug-12-24 10:53PM	GOSS Stock Earnings: Gossamer Bio Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
05:10PM	Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates (Zacks)
04:15PM	Gossamer Bio: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-25-24 02:35AM	Why Is Gossamer Bio, Inc. (GOSS) the Best One-Dollar Stock to Buy Now? (Insider Monkey)
Jun-13-24 03:35PM	The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street (InvestorPlace)
Jun-07-24 04:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.60% -6.09%
May-14-24 04:01PM	Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference (Business Wire)
May-10-24 04:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-07-24 10:56PM	GOSS Stock Earnings: Gossamer Bio Misses EPS for Q1 2024 (InvestorPlace) -6.30%
05:15PM	Gossamer Bio: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
05:11AM	Gossamer Bio and Chiesi partner for pulmonary hypertension treatment (Pharmaceutical Technology)
04:31AM	Gossamer Bio and Chiesi link for pulmonary hypertension treatment (Pharmaceutical Technology)
03:17PM	Loading…
May-06-24 03:17PM	Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide (Benzinga) +5.50%
08:17AM	UPDATE 1-Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition (Reuters)
08:11AM	Gossamer sells rights to drug it hopes can rival a new Merck therapy (BioPharma Dive)
07:41AM	Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment (Reuters)
07:30AM	Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications (Business Wire)
May-03-24 08:02AM	Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine (Business Wire)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-12-24 07:31AM	Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors (Business Wire)
Mar-07-24 09:55AM	Should You Buy Gossamer Bio (GOSS) After Golden Cross? (Zacks) -7.95%
Mar-05-24 10:52PM	GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023 (InvestorPlace)
07:55AM	Gossamer Bio Posts Narrower Loss In Q4 - Quick Facts (RTT News)
07:40AM	Gossamer Bio: Q4 Earnings Snapshot (Associated Press Finance)
07:31AM	Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update (Business Wire)
Feb-27-24 03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey)
Jan-31-24 02:23PM	7 Micro-Cap Stocks That Could Majorly Surprise Investors (InvestorPlace)
Jan-22-24 10:53AM	5 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-08-24 04:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.24% +7.16%
Dec-13-23 04:01PM	Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023 (Business Wire)
Dec-05-23 04:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.31%
07:01AM	Gossamer Bio Appoints Bob Smith as Chief Commercial Officer (Business Wire)
Nov-29-23 07:01AM	Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors (Business Wire)
Nov-09-23 08:11AM	Gossamer Bio Inc (GOSS) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) -7.56%
07:41AM	Gossamer Bio: Q3 Earnings Snapshot (Associated Press Finance)
07:31AM	Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Oct-23-23 10:08AM	12 Best Penny Stocks to Buy Under $1 (Insider Monkey) -6.46%
Oct-03-23 04:08PM	Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs (Business Wire) -5.57%
Sep-07-23 07:44AM	Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023 (Business Wire)
Aug-28-23 08:20AM	TENX: Second Quarter Results (Zacks)
Aug-08-23 04:41PM	Gossamer Bio: Q2 Earnings Snapshot (Associated Press Finance) -5.43%
04:01PM	Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Jul-24-23 04:16PM	Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results (Business Wire) -6.72%
Jul-20-23 07:56AM	Gossamer Bio Announces $212 Million Private Placement Financing (Business Wire) -31.87%
Jun-23-23 06:24AM	TENX: Notice of Allowance Increases Confidence (Zacks Small Cap Research)
May-18-23 07:05AM	Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference (Business Wire) +7.58%
May-13-23 08:15AM	In the wake of Gossamer Bio, Inc.'s (NASDAQ:GOSS) latest US$15m market cap drop, institutional owners may be forced to take severe actions (Simply Wall St.)
May-09-23 04:13PM	Gossamer Bio: Q1 Earnings Snapshot (AP Finance)
04:01PM	Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Apr-04-23 12:38PM	After Pausing Recruitment, Gossamer Bio Terminates All Studies With CNS Lymphoma Candidate (Benzinga) -9.38%
Mar-17-23 07:46AM	Gossamer Bio: Q4 Earnings Snapshot (AP Finance) -8.47%
07:31AM	Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update (Business Wire)
Mar-07-23 03:37PM	Analyst Downgrades Gossamer Bio As Merck's Sotatercept Might Overshadow Seralutinib's Success (Benzinga)
Mar-03-23 11:40AM	15 Most Shorted Stocks Right Now on Wall Street (Insider Monkey)
Feb-01-23 04:25PM	7 Top Short-Squeeze Candidates to Watch in February (InvestorPlace) +7.20%
Jan-04-23 12:00PM	Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +5.39%
09:35AM	Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Dec-26-22 09:41AM	Bullish insiders at Gossamer Bio, Inc. (NASDAQ:GOSS) loaded up on US$1.2m of stock earlier this year (Simply Wall St.)
Dec-06-22 01:19PM	Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis (Benzinga) -74.60%
10:00AM	Gossamer Bio Shares Plummet As Hypertension Trial Fall Short Of Expectation (Benzinga)
08:19AM	Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug (MarketWatch)
07:15AM	Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH (Business Wire)
Nov-17-22 02:37PM	Analyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH Trial (Benzinga)
Nov-08-22 12:00PM	What Makes Gossamer Bio (GOSS) a New Buy Stock (Zacks)
Nov-03-22 04:01PM	Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Oct-24-22 08:30AM	Goldman Sachs Says These 2 Buy-Rated Stocks Have at Least 60% Upside Potential (TipRanks)
Aug-29-22 08:11AM	With 62% ownership of the shares, Gossamer Bio, Inc. (NASDAQ:GOSS) is heavily dominated by institutional owners (Simply Wall St.)
Aug-09-22 08:01AM	Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Jul-21-22 06:21PM	2 Strong Buy Stocks That In-The-Know Bigwigs Are Pouring Money Into (TipRanks)
Jul-20-22 11:33AM	Squeezable AMC, GameStop stocks break out to multi-month highs (MarketWatch)
Jul-19-22 12:00PM	Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy (Zacks) +6.29%
09:46AM	The Co-Founder of Gossamer Bio, Inc. (NASDAQ:GOSS), Faheem Hasnain, Just Bought 3.8% More Shares (Simply Wall St.)
Jul-18-22 09:55AM	Wall Street Analysts See a 52% Upside in Gossamer Bio (GOSS): Can the Stock Really Move This High? (Zacks)
Jul-13-22 07:15AM	Gossamer Bio Announces $120 Million Private Placement Financing (Business Wire) +31.90%
Jun-09-22 08:30AM	Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinibs Potential for the Treatment of PAH (Business Wire)
May-26-22 09:55AM	Wall Street Analysts Believe Gossamer Bio (GOSS) Could Rally 113%: Here's is How to Trade (Zacks)
May-23-22 09:55AM	Gossamer Bio (GOSS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
May-10-22 04:01PM	Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update (Business Wire) +11.70%
May-06-22 12:20PM	Is Gossamer Bio (NASDAQ:GOSS) Weighed On By Its Debt Load? (Simply Wall St.) -7.01%
Apr-25-22 07:29AM	Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update (Business Wire)
Mar-03-22 04:01PM	Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update (Business Wire) +6.19%
Feb-28-22 07:01AM	Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022 (Business Wire)

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Aranda Richard	Chief Medical Officer	Jun 24 '24	Sale	0.66	1,908	1,260	196,891	Jun 25 06:24 PM
Hasnain Faheem	President & CEO	Jun 21 '24	Buy	0.67	372,000	250,282	5,408,073	Jun 24 05:52 PM
Giraudo Bryan	COO/CFO	Jun 18 '24	Buy	0.59	100,000	59,110	480,010	Jun 20 08:21 PM
Smith Robert Paul JR	Chief Commercial Officer	Jun 17 '24	Buy	0.60	25,000	15,050	25,000	Jun 20 08:20 PM
Christian Waage	EVP, Tech Ops and Admin	Mar 27 '24	Sale	1.16	6,430	7,430	585,934	Mar 28 06:16 PM
Giraudo Bryan	COO/CFO	Mar 27 '24	Sale	1.16	6,430	7,431	92,737	Mar 28 06:05 PM
Hasnain Faheem	President & CEO	Mar 27 '24	Sale	1.16	23,172	26,773	120,293	Mar 28 06:01 PM
Aranda Richard	Chief Medical Officer	Mar 18 '24	Sale	1.33	4,018	5,342	198,799	Mar 19 06:50 PM
Peterson Caryn	EVP, Regulatory Affairs	Mar 18 '24	Sale	1.33	4,018	5,343	49,833	Mar 19 06:50 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GOSS

Gossamer Bio Inc

Upgrade your FINVIZ experience